权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Molecular and Cellular Phenotype of Aging and iPS Cells

衰老和 iPS 细胞的分子和细胞表型

基本信息

批准号：
7836567
负责人：
KENNETH I WEINBERG
金额：
$ 99.97万
依托单位：
STANFORD UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2010
资助国家：
美国
起止时间：
2010-09-30 至 2012-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7836567
关键词：
Address Affect Age Age-Years Aging Aging-Related Process Applications Grants Biological Assay Biology Cardiac Cell Aging Cell Line Cell physiology Cells Clinical DNA Damage DNA Repair DNA-Directed DNA Polymerase Derivation procedure Disease ES Cell Line Elderly Embryo Endothelial Cells Epigenetic Process Ethics Fibroblasts Future Gene Expression Genes Grant Heart failure Hematopoietic stem cells Homologous Gene Human Immune In Vitro Individual Karyotype Length Literature Mating Types Measurement Measures Methylation Molecular Muscle satellite cell Mutation Neurodegenerative Disorders Newborn Infant Nuclear Oxidative Stress Patients Phenotype Population Production Reactive Oxygen Species Regulation Replacement Therapy Somatic Cell Source Stem cells Stroke Telomerase Telomere Shortening Testing Therapeutic Tissues Translations United States National Institutes of Health Viral adult stem cell age effect age group aged cell age human embryonic stem cell in vivo induced pluripotent stem cell insight knock-down middle age novel older patient pluripotency public health relevance regenerative self-renewal senescence stem stem cell therapy telomere vector young adult

项目摘要

DESCRIPTION (provided by applicant): Induced pluripotent stem (iPS) cells are a novel source for derivation of donor populations in cell replacement therapy. However, because the major applications of iPS cells relate to diseases predominately affecting elderly populations such as heart failure, stroke, and neurodegenerative disease, it is likely that the majority of iPS cells derived for future clinical use will be isolated from senescent and aged somatic cell populations of elderly patients. Currently it is not known how aging and senescence affect the capacity of somatic cells to be reprogrammed. It is also not known whether aging and senescence affect the subsequent differentiation of iPS cells and the efficiency of their iPS cell derivatives. This NIH Challenge Grant proposal will address these questions. We propose to derive iPS cell lines from fibroblasts of elderly (>70 years old), middle-age (40-50 years old), and newborn (1-2 week old) patients. We will assess whether aging and senescence may impair reprogramming efficiency as well as gene expression, capacity for pluripotency, and sensitivity to oxidative stress and DNA damage in iPS cells. We will differentiate iPS cells derived from patients of all age groups into functional endothelial cells and compare the in vitro and in vivo functions of these cells with endothelial cells derived from human embryonic stem cells and human microvascular endothelial cells (HMECs). Finally, we will compare iPS cells derived from elderly patients with a rapidly aged line of iPS cells in which the Sirtuin (silent mating type information regulation 2 homolog) 6 (also known as SIRT6) gene has been knocked down. Collectively, these results will provide valuable information for future clinical translation of patient-specific iPS cell therapies. PUBLIC HEALTH RELEVANCE: Aging has been shown to impair the integrity, function, and proliferative capacity of many adult stem cells such as hematopoietic stem cells, muscle satellite cells, and cardiac progentior cells. We propose to analyze the effects of aging and senescence upon somatic cells that undergo cellular reprogramming into iPS cells. This study will provide valuable insight into the process of aging and yield useful information on how patient-specific pluripotent cells may be used in elderly patients suffering from such diseases as heart failure, stroke, and neurodegenerative disease.

描述（由申请人提供）：诱导多能干细胞（iPS）是细胞替代疗法中供体群体衍生的新来源。然而，由于iPS细胞的主要应用涉及主要影响老年人群的疾病，如心力衰竭、中风和神经退行性疾病，因此很可能将来用于临床的大多数iPS细胞将从老年患者的衰老和老化体细胞群中分离。目前还不清楚衰老和衰老如何影响体细胞的重编程能力。也不知道衰老和衰老是否影响iPS细胞的后续分化及其iPS细胞衍生物的效率。这项NIH挑战补助金提案将解决这些问题。我们建议从老年（>70岁）、中年（40-50岁）和新生儿（1-2周龄）患者的成纤维细胞中获得iPS细胞系。我们将评估衰老和衰老是否会损害iPS细胞的重编程效率以及基因表达、多能性能力、对氧化应激和DNA损伤的敏感性。我们将从所有年龄组的患者中获得的iPS细胞分化为功能性内皮细胞，并将这些细胞的体外和体内功能与来自人胚胎干细胞和人微血管内皮细胞（HMEC）的内皮细胞进行比较。最后，我们将比较来自老年患者的iPS细胞与快速老化的iPS细胞系，其中Sirtuin（沉默交配型信息调节2同源物）6（也称为SIRT 6）基因已被敲除。总的来说，这些结果将为未来患者特异性iPS细胞疗法的临床转化提供有价值的信息。公共卫生相关性：衰老已被证明会损害许多成体干细胞如造血干细胞、肌肉卫星细胞和心脏祖细胞的完整性、功能和增殖能力。我们建议分析衰老和衰老对体细胞的影响，这些体细胞经历细胞重编程为iPS细胞。这项研究将为衰老过程提供有价值的见解，并提供有关如何将患者特异性多能细胞用于患有心力衰竭，中风和神经退行性疾病等疾病的老年患者的有用信息。